drug · gene
axicabtagene ciloleucel
Phase 3updated 5mo agoby $GILD GILEAD SCIENCES, INC.🔗 ChEMBL
Phase 3community read0 votes
Gene drug with a maximum clinical stage of Approval (across all indications), with an approval for follicular lymphoma and diffuse large b-cell lymphoma and 5 investigational indications.
indications
indications
DLBCL
targets
B-lymphocyte antigen CD19
all catalysts(0)
nothing on the calendar yet
Trials studying axicabtagene ciloleucel
- —Long-Term Follow-Up Study After Gene-Modified Cell Treatment in Kite Studies
- phase3A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- phase3Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy
- phase3Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma
- phase2Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2)
- phase2Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- phase2Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma
- phase2A Study of Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
News(6)
- Unlocking cell surface protein research with site-specific labelingApplications in flow cytometry, cell sorting, target validation, and therapeutic discoverybiospace · 20d ago
- CEO O’Day tells Fierce how Gilead’s cancer, inflammation expansion has reached ‘critical mass’Following a steady stream of acquisitions that culminated in three biotech buyouts earlier this year, Gilead has now reached “critical mass” in its efforts to diversify into oncology and inflammati…fiercebiotech · 24d ago
- J&J hands lymphoma bispecific CAR T back to AbelZetaJohnson & Johnson secured rights to prizlon-cel in 2023 for $245 million upfront. The asset in June last year showed a 100% response rate as a second-line option in a Phase 1b study for 10 patients…biospace · 1mo ago
- Lilly, AbbVie climb aboard in vivo CAR T train—but safety remains a hurdleSafety will be the key determinant of in vivo CAR T therapies, according to H.C. Wainwright’s Mitchel Kapoor, who noted that convenience and efficacy won’t be enough to impress investors in this sp…biospace · 2mo ago
- Study of Yescarta patients reveals genetic red flags for CAR-T therapy side effectsA new analysis of patients who took part in clinical trials for Kite Pharma’s CAR-T cell therapy Yescarta has revealed genetic signatures of toxicity risk, potentially providing a path forward for…fiercebiotech · 2mo ago
- Repligen strikes $1.5B BioLife buyout to bag cell therapy product pharmas rely onTop-selling cell therapies from BMS, J&J and Gilead depend on a BioLife product, positioning Repligen to use the takeover to increase its exposure to the modality.biospace · 2mo ago
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that